



RepliCel™

TSX:V: RP | OTCQB: REPCF

Using Cells for Healing

RCI-02 – Dermatology Injector Device

RCI-02 is a next-generation dermal injector designed to provide an improved level of control and precision for intradermal (dermis), subcutaneous (fat) or intramuscular injections. The injector has broad application for dermatological injections of cellular products, fillers, hyaluronic acids, fat and collagen injections which would benefit from increased control over injection volumes and depth.



Benefits

- Delivery of a variety of injectable substances including cells, dermal fillers, drugs or biologics
- Enables broad, shallow injections for fine wrinkles
- Increased precision and ease of application
- Improved control and repeatable delivery
- Reduction in use of local anaesthetics
- Less pain and bruising
- Improved consistency of procedure
- Comfort grip for ease of use
- Increased surface area coverage
- Quicker procedure times

Features

- Digital, touch-screen controls
- Programmable depth & volume
- Peltier element numbs skin, reducing use of local anesthetic (removable for sterilization)
- Interchangeable needle heads
- Multiple needle configurations from a single needle to a 16 needle configuration (4x4) on one head
- Pre-filled disposable cartridges
- High-powered LED light

This Fact Sheet is provided by RepliCel Life Sciences Inc. as a convenience for potential licensees and or investors. More details about the business and its risks can be found in the company's press releases and filings with the U.S. Securities and Exchange Commission or the Canadian Securities Administrators. This Fact Sheet may contain forward-looking statements and actual results may differ materially from such statements.

Design Features

Product Details


RCI-02 is the world's first motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection anaesthetising, and interchangeable needle head configurations. Interchangeable needle configurations enable a variety of procedures, increase surface area coverage and speed-up procedure times. By relying on electrically powered mechanisms (instead of tactile thumb pressure) and digital controls, RCI-02 automates, standardizes and simplifies the injection process.

Equipped with a touch screen on its accompanying docking station, the device's programmability allows for the delivery of precise quantities of material, at specific depths, through various gauge needle configurations, on a single plain or trailing through multi-planes as the needle retracts through the skin.

Pre-filled Disposable Cartridges



Peltier Element



Development Status

Prototypes are now being built to recently-announced design specifications for industrial and regulatory testing, the data from which will be used to prepare for an application for CE mark clearance to market the injector in Europe in 2016.

Licensing Opportunity

RepliCel's business model is focused on leveraging its expertise in developing assets that are then licensed to partners for co-development and commercialization. RepliCel is actively engaging licensing partners for its dermal injector device.

Contact

Lee Buckler, President & CEO
 2020 – 401 West Georgia Street
 Vancouver, BC V6B 5A1
 Tel: 604.248.8693 | Email: lee@replixel.com
www.replixel.com



RepliCel™
 Using Cells for Healing